Free tool
FAERS Monitor: Crestor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021366 or its brand name (Crestor, Rosuvastatin Calcium). Reports on generic versions are filed under their own applications.
Reports
207,891
Serious
140,698
68% of reports
Hospitalization
64,548
Death reported
12,446
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue12,643
- nausea10,873
- diarrhoea10,009
- drug ineffective9,957
- dyspnoea9,810
- off label use9,289
- myalgia9,259
- pain8,962
- headache8,466
- dizziness8,274
- arthralgia7,767
- asthenia7,654
- pain in extremity7,094
- malaise6,885
- fall6,436
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2,921 |
| 2005 | 2,047 |
| 2006 | 3,055 |
| 2007 | 2,421 |
| 2008 | 3,898 |
| 2009 | 5,904 |
| 2010 | 7,391 |
| 2011 | 9,524 |
| 2012 | 11,040 |
| 2013 | 7,390 |
| 2014 | 8,106 |
| 2015 | 10,275 |
| 2016 | 10,288 |
| 2017 | 9,901 |
| 2018 | 11,123 |
| 2019 | 11,854 |
| 2020 | 11,540 |
| 2021 | 11,928 |
| 2022 | 12,119 |
| 2023 | 12,833 |
| 2024 | 13,919 |
| 2025 | 15,891 |
| 2026 | 12,523 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,846,268 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myalgiaSignal | 9,259 | 5.8 | 5.7 | 34,796 |
| pain in extremitySignal | 7,094 | 2.5 | 2.4 | 6,149 |
| astheniaSignal | 7,654 | 2.1 | 2.0 | 4,289 |
| fall | 6,436 | 2.0 | 1.9 | 3,087 |
| arthralgia | 7,767 | 1.9 | 1.9 | 3,353 |
| dyspnoea | 9,810 | 1.8 | 1.7 | 3,294 |
| dizziness | 8,274 | 1.7 | 1.7 | 2,346 |
| fatigue | 12,643 | 1.7 | 1.6 | 3,336 |
| malaise | 6,885 | 1.6 | 1.6 | 1,547 |
| diarrhoea | 10,009 | 1.6 | 1.5 | 2,150 |
| pain | 8,962 | 1.5 | 1.5 | 1,431 |
| nausea | 10,873 | 1.4 | 1.4 | 1,248 |
| headache | 8,466 | 1.4 | 1.3 | 865 |
| off label use | 9,289 | 1.1 | 1.1 | 49 |
| drug ineffective | 9,957 | 0.8 | 0.7 | 779 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.